UroGen Pharma
URGN
UroGen Pharma (URGN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.28
- EPS estimate
- −$0.28
- EPS surprise
- +0.00%
- Revenue surprise
- +11.39%
- Revenue
- $72.5M
- Revenue estimate
- $65.0M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.28 | −$0.28 | +0.00% | $72.5M | SEC |
| Q1 2026 | May 6, 2026 | −$0.48 | −$0.47 | +2.57% | $51.0M | SEC |
| Q4 2025 | Mar 2, 2026 | −$0.50 | −$0.54 | −7.48% | $37.8M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.69 | −$0.69 | +0.33% | $27.5M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.86 | −$1.05 | −21.43% | $24.2M | SEC |
| Q1 2025 | May 12, 2025 | −$0.80 | −$0.92 | −15.10% | $20.3M | SEC |
| Q4 2024 | Mar 10, 2025 | −$0.72 | −$0.80 | −11.16% | $24.6M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.82 | −$0.55 | +32.69% | $25.2M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.83 | −$0.91 | −9.38% | $21.8M | SEC |
| Q1 2024 | May 13, 2024 | −$0.87 | −$0.97 | −11.93% | $18.8M | SEC |
| Q4 2023 | Mar 14, 2024 | −$0.68 | −$0.72 | −5.88% | $23.5M | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.85 | −$0.68 | +19.62% | $20.9M | SEC |
| Q2 2023 | Aug 10, 2023 | −$1.14 | −$1.03 | +9.33% | $21.1M | SEC |
| Q1 2023 | May 11, 2023 | −$1.33 | −$1.30 | +2.26% | $17.2M | SEC |
| Q4 2022 | Mar 22, 2023 | −$1.07 | −$1.22 | −13.67% | $18.1M | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.16 | −$1.13 | +2.31% | $16.1M | SEC |
| Q2 2022 | Aug 11, 2022 | −$1.28 | −$1.18 | +7.45% | $16.6M | SEC |
| Q1 2022 | May 10, 2022 | −$1.33 | −$1.25 | +6.25% | $13.6M | SEC |
| Q4 2021 | Mar 21, 2022 | −$1.18 | −$1.27 | −8.09% | $16.2M | SEC |
| Q3 2021 | Nov 15, 2021 | −$1.28 | −$1.35 | −5.47% | $11.4M | SEC |
Quarterly revenue
Frequently asked questions
When did UroGen Pharma (URGN) last report earnings?
UroGen Pharma last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did URGN beat earnings estimates?
UroGen Pharma reported EPS of −$0.28 for Q2 2026, in line with the −$0.28 consensus estimate.
How much revenue did URGN report last quarter?
UroGen Pharma reported $72.5M in revenue for Q2 2026, against a consensus estimate of $65.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.